About Apogenix
The biopharmaceutical company Apogenix GmbH develops novel protein therapeutics for the targeted manipulation of apoptosis (programmed cell death). Apoptosis is a natural, tightly controlled process that rids the body of old, damaged or degenerate cells. In many disease conditions, this process is out of balance. This has resulted in either excessive death of healthy cells and healthy tissue (e.g., in acute "Graft-versus-Host Disease", stroke and spinal cord injuries) or an insufficient degradation of damaged and degenerated cells (e.g. in tumors). Apogenix is a spin-off of the German Cancer Research Center (DKFZ) based in Heidelberg. In 2005, the company received €15 million in a first round of financing from the investment companies of the family of SAP co-founder Dietmar Hopp.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of Apogenix
Here you will find Apogenix GmbH
Last viewed contents
Medgenics consolidates corporate and R&D operations into new office facility
LECO Corporation - St. Joseph, USA
Eckert & Ziegler subsidiary IBt Bebig acquires specialist for medical planning software
Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
